Belarusian scientists have brought to the domestic market a locally produced medicine for patients with epilepsy and neurological disorders, offering a full alternative to imported drugs, according to
BelTA, a partner of TV BRICS.
The new medication has received recognition at the national level, the experts stated. The National Academy of Sciences of Belarus (NASB) included the new drug among the top ten scientific results of 2025 in the field of fundamental and applied research, underscoring its importance for the national pharmaceutical industry.
Researchers worked on the drug for more than four years. According to developers, the Belarusian medicine is a 100 per cent equivalent of the original product in composition, while its price is around 50 per cent lower.
“We are the only ones who have replicated the original drug. Not only in terms of design, dosage, and form, but also in terms of impurity profile,” stressed Head of Research and Development at Academpharm Vladislav Gudovich.
Specialists explained that despite the seemingly simple capsule formulation, the development process required precise selection of excipients and active ingredients, which posed major technological challenges. The project involved a wide range of experts from Academpharm, reflecting the complexity of modern pharmaceutical development.
Within just a few months of entering the market, sales of the new medicine in Belarusian pharmacies exceeded US$343.7 thousands, reflecting strong demand for affordable, domestically produced pharmaceutical products.
Photo: SweetBunFactory /
iStock